

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 23, 2019

SECOND SIGHT MEDICAL PRODUCTS, INC.

(Exact Name of Registrant as Specified in Its Charter)

California

(State or Other Jurisdiction of Incorporation)

001-36747

(Commission File Number)

02-0692322

(IRS Employer Identification No.)

12744 San Fernando Road, Suite 400

Sylmar, California 91342

(Address of Principal Executive Offices)

(818) 833-5000

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|----------------------------|--------------------------|--------------------------------------------------|
| Common Stock | EYES | NASDAQ |
| Warrants | EYESW | NASDAQ |

ITEM 7.01. REGULATION FD DISCLOSURE

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight") intends to use during a presentation at the B. Riley FBR Investor Conference in Beverly Hills, CA on May 23, 2019 (the "Presentation Materials") is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, the B. Riley FBR Investor Conference presentation will be webcast at 3:30 P.M. Pacific Daylight Time on May 23, 2019 at <http://www.wsw.com/webcast/brileyfbr3/eyes>. The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.secondsight.com, under the Investors section. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No. Description

99.1 Second Sight Medical Products, Inc. Investor Presentation dated May 23, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 23, 2019

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ John T. Blake

By: John T. Blake
Chief Financial Officer

Second Sight Medical Products, Inc.
(NASDAQ: EYES)

Discover
Life in a New Light®

B. Riley FBR Investor Conference
May 23, 2019



This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans" or "planned," "strategy," "goal," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 19, 2019, our most recent 10-Q, filed on May 15, 2019 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

Argus® II

Retinal Prosthesis

Legacy Technology Development Platform

- First and only FDA approved retinal prosthesis
- 20+ years and ~\$200M invested to develop underlying technology and commercialize
- Durable array design (10+ years) and proprietary software algorithms with 300+ implants
- Approved for individuals with advanced retinitis pigmentosa (bare-light and no-light perception) in U.S.

Orion®

Visual Cortical Prosthesis

Platform for Broad Commercialization

- Transformational technology with U.S. human trial initiated in Q1 2018
- Larger potential addressable market with a significant unmet need; includes glaucoma, diabetic retinopathy, optic nerve disease and eye injury/trauma
- Bypasses the retina and optic nerve to directly stimulate the portion of the brain responsible for vision

Orion Visual Cortical Prosthesis Overview


Orion is an investigational visual cortical prosthesis that induces visual perception in blind individuals



Video Link: <https://youtu.be/yiaKNmUlcqs>

Orion[®]: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness

*The addressable market for Orion is potentially over 70,000 individuals in the U.S.;
a multi-billion dollar market opportunity*



Conducting a six subject feasibility study at Ronald Reagan UCLA Medical Center and Baylor College of Medicine

- Six subjects cleared for home use

Initial results from our testing include the following:

- Stimulation parameters are within expected ranges and field of view appears to be larger than Argus
- Observations from rehab sessions indicate subjects are able to do things with Orion that they could not do without, examples include:
 - Locate people in front of them
 - Walk down sidewalk independently and identify parked cars and driveways
 - Identify cue ball and striped balls on a pool table
 - Sort light from dark laundry
 - Identify and blow out candles on a birthday cake
- Currently, system on versus system off:
 - Square localization: 4 of 5 subjects significantly better
 - Direction of motion: 4 of 5 subjects significantly better
 - FLORA: 5 of 5 subjects are showing benefit or mild benefit



Performance data from feasibility subjects will be used to determine next steps in 2019, including discussions with FDA to finalize clinical and regulatory pathway as part of Breakthrough Devices program



Execute Orion clinical and R&D programs

- Positive interim results of six subject U.S. Early Feasibility Study at UCLA and Baylor
- R&D to iterate cortical prosthesis and external components in preparation for pivotal trial
- Orion designated FDA Breakthrough Device for expedited pathway to commercialization



Improve the artificial vision user experience

- Multiple research projects to enhance visual acuity and create a richer user experience
- Examples include object and facial recognition, distance filtering, thermal imaging and eye tracking
- Technologies can be integrated in both Argus and Orion platforms



Leverage Argus II technology and core competencies

- Leverage key competencies in clinical, rehabilitation and market development to benefit Orion
- Restructuring implemented to reduce commercial and production activities
- We remain committed to supporting all Argus users



Centers of Excellence (COE) model and artificial vision rehabilitation

- Centers of Excellence model to build regional artificial vision centers for Argus and Orion
- Best practices development and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes for all artificial vision patients



Effective patient outreach & screening with U.S. patient database

- Effective patient outreach programs and a multi-step patient qualification process applicable to Argus and Orion
- Large and growing U.S. database that includes over 1,000 potential Orion candidates



Market access & reimbursement expertise

- Argus is an established therapy in over a dozen markets globally
- Achieved highest CMS outpatient reimbursement rate in U.S. at \$152.5k for 2019
- CMS' recent proposals to provide reimbursement for Breakthrough Devices on approval are encouraging



Orion leverages Argus II technology platform

- Established technology with 10+ years proven implant durability
- Proprietary algorithms for artificial vision
- Over 85 issued U.S. patents for Orion

Object & Facial Recognition

Receive additional auditory and/or haptic information integrated with their artificial vision

Thermal Imaging

Infrared imaging would allow users to visualize warm objects such as people in a room




Depth-Based Decluttering

Allow users to filter out objects further than a defined distance




Eye Tracking


Move the implant field of view in conjunction with the movement of the user's eyes

Research projects to drive potential benefit for Argus and Orion users



Orion

-  Orion Early Feasibility Study and release interim data from first six subjects at six months and one year
-  Agreement on pivotal and post-market trial designs via the FDA's Breakthrough Device Program
-  Enroll additional subjects in Early Feasibility Study



| (USD \$ in thousands) | Q1 2019 | Q1 2018 |
|-----------------------------------------|-----------|-----------|
| Argus® II Implants | 10 | 16 |
| Revenue | \$1,128 | \$976 |
| Gross Profit | \$397 | \$308 |
| Net Loss | \$(9,700) | \$(9,753) |
| Non-GAAP Adjusted Net Loss ¹ | \$(6,378) | \$(8,512) |

1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

| (USD \$) | March 31, 2019 | December 31, 2018 |
|------------------------------------------|----------------|-------------------|
| Cash and cash equivalents | \$31.7 million | \$4.5 million |
| Cash runway expected into Q2 2020 | | |
| Debt | \$0 | \$0 |



Will McGuire
President & CEO

- 20+ years experience in medical device industry
- Extensive leadership experience across both public and private companies
- Most recently as President of Americas Commercial for Volcano Corporation (acquired by Phillips for \$1.2B in 2015).



John Blake
Chief Financial Officer

- 15+ years experience in public company finance and accounting
- Extensive transactional and M&A experience in high-growth medical device and biotech
- Former leadership roles at aTyr Pharma and Volcano Corporation (acquired by Phillips for \$1.2B in 2015)



Steve Okland
Chief Commercial Officer

- 25+ years experience in medical device industry
- Commercialization leadership roles at Medivance (acquired by Bard Medical for \$250M in 2011), Spectranetics, Boston Scientific Corporation and Johnson & Johnson Medical



William Patrick Ryan
Chief Operating Officer

- 20+ years experience in medical device industry
- Extensive COO leadership experience (Synaptive Medical, Lucerno Dynamics, Insulet Corporation, Alphatec Spine)
- Leadership positions at Guidant & Abbott Vascular



Orion is a large market opportunity that's more than 50x the current RP market

- Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury
- Six subject feasibility study at UCLA and Baylor underway with good early results and additional interim data in 2019
- FDA Breakthrough Device designation provides expedited regulatory and clinical pathway

Orion leverages Argus® II technological backbone

- Orion leverages Argus technology including implantable array, externals and proprietary software / algorithms for creating artificial vision
- Orion also leverages reimbursement success, patient outreach and screening expertise as well as artificial vision rehabilitation competencies

Future technologies under development beneficial to Argus II and Orion

- Eye-tracking, thermal imaging and depth-based decluttering provide improved or more useful vision
- Object recognition and facial recognition create enhanced user experience

Second Sight Medical Products, Inc.

12744 San Fernando Road
Suite 400
Sylmar, CA 91342
Main: 818-833-5000
www.secondsight.com

Will McGuire
President & CEO
Direct: 818-833-5040
wmcguire@secondsight.com

Retail Investor Relations

Greg Falesnik
Managing Director
MZ North America
Direct: 949-385-6449
Greg.Falesnik@mzgroup.us

Institutional Investor Relations

Lisa Wilson
President
In-Site Communications, Inc.
Direct: 212-452-2793
lwilson@insitecony.com
